1. Home
  2. DOUG vs DERM Comparison

DOUG vs DERM Comparison

Compare DOUG & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Douglas Elliman Inc.

DOUG

Douglas Elliman Inc.

HOLD

Current Price

$2.02

Market Cap

178.2M

Sector

Real Estate

ML Signal

HOLD

Logo Journey Medical Corporation

DERM

Journey Medical Corporation

HOLD

Current Price

$6.32

Market Cap

190.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOUG
DERM
Founded
1911
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Building operators
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
178.2M
190.3M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
DOUG
DERM
Price
$2.02
$6.32
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$12.67
AVG Volume (30 Days)
306.4K
156.9K
Earning Date
05-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
118.68
34.72
EPS
N/A
N/A
Revenue
$955,578,000.00
$61,858,000.00
Revenue This Year
N/A
$39.72
Revenue Next Year
N/A
$63.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
10.20
52 Week Low
$1.53
$4.31
52 Week High
$3.19
$9.56

Technical Indicators

Market Signals
Indicator
DOUG
DERM
Relative Strength Index (RSI) 68.96 47.99
Support Level $1.70 $5.85
Resistance Level $2.05 $6.59
Average True Range (ATR) 0.08 0.35
MACD 0.02 -0.02
Stochastic Oscillator 94.72 42.11

Price Performance

Historical Comparison
DOUG
DERM

About DOUG Douglas Elliman Inc.

Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.

About DERM Journey Medical Corporation

Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.

Share on Social Networks: